por
Barbara Kram, Editor | November 21, 2005
Standard on all AXIOM Luminos TF systems is an easy-to-use intuitive user interface, which allows physicians to complete more exams in less time. Ergonomic handles positioned in the front of the system provide for improved operator comfort and flexibility, while tableside controls are configured to provide for the most commonly used features.
The AXIOM Luminos TF provides all of the performance standards common to other AXIOM products, including enhanced workflow and efficiency, optimal image quality, reduced radiation dose, and patient comfort. The latest software capabilities help to simplify user operations. It is equipped with syngo, Siemens' standard user interface, which helps to further optimize workflow in radiology units. Additionally, the technology is a PC-based digital platform that runs on Windows NT, which requires low maintenance and provides high uptime.

Ad Statistics
Times Displayed: 72465
Times Visited: 2387 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
**
Also at RSNA: Siemens Advances Ultrasound Imaging with New Capabilities and Technology Enhancements for ACUSON Sequoia Platform
Siemens Medical Solutions continues to advance ultrasound imaging not only with its recent acquisition of Sensant Corporation and silicon ultrasound transducer technology, but also with the introduction of the Encompass II release for the ultra-premium ACUSON Sequoiaultrasound platform. (The company will showcase its complete suite of ultrasound systems at RSNA.)
Siemens is dedicated to offering its customers unequaled clinical value and performance, and is committed to the continuous development of high resolution and high sensitivity technology requisite for future clinical applications. For example, the company's Cadence contrast pulse sequencing (CPS) technology offers new levels of contrast detection and specificity for molecular imaging with ultrasound. This will ultimately result in expanded clinical applications, increased diagnostic confidence, and real-time prediction of disease processes. The company's pre-clinical trials in molecular imaging show promise in future applications for assessment of inflammation, angiogenesis, and thrombus formation.
A second example is silicon ultrasound technology, which is expected to offer efficient volumetric 4D imaging for a wide range of applications, enabling clinicians to visualize a greater level of detail within both conventional and volumetric 4D ultrasound images. The company will integrate the technology into its complete range of ultrasound systems, and expects it to be commercially available within two years.